TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Titel:
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Auteur:
Oxnard, G.R. Yang, J.C.-H. Yu, H. Kim, S.-W. Saka, H. Horn, L. Goto, K. Ohe, Y. Mann, H. Thress, K.S. Frigault, M.M. Vishwanathan, K. Ghiorghiu, D. Ramalingam, S.S. Ahn, M.-J.